Found 2 results
Filters: Author is N.L. Satiroglu-Tufan  [Clear All Filters]
Y. Dodurga, Satiroglu-Tufan, N. L., Tataroglu, C., and Kesen, Z., Incidence of fibroblast growth factor receptor 3 gene (FGFR3) A248C, S249C, G372C, and T375C mutations in bladder cancer, vol. 10, pp. 86-95, 2011.
Basilico C and Moscatelli D (1992). The FGF family of growth factors and oncogenes. Adv. Cancer Res. 59: 115-165.   Billerey C, Chopin D, Aubriot-Lorton MH, Ricol D, et al. (2001). Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am. J. Pathol. 158: 1955-1959.   Cappellen D, De Oliveira C, Ricol D, de Medina S, et al. (1999). Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat. Genet. 23: 18-20. PMid:10471491   Chesi M, Brents LA, Ely SA, Bais C, et al. (2001). Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood 97: 729-736. PMid:11157491   Chow NH, Cairns P, Eisenberger CF, Schoenberg MP, et al. (2000). Papillary urothelial hyperplasia is a clonal precursor to papillary transitional cell bladder cancer. Int. J. Cancer 89: 514-518.<514::AID-IJC8>3.0.CO;2-H   Hirao S, Hirao T, Marsit CJ, Hirao Y, et al. (2005). Loss of heterozygosity on chromosome 9q and p53 alterations in human bladder cancer. Cancer 104: 1918-1923. PMid:16149093   Jaye M, Schlessinger J and Dionne CA (1992). Fibroblast growth factor receptor tyrosine kinases: molecular analysis and signal transduction. Biochim. Biophys. Acta 1135: 185-199.   Johnson DE and Williams LT (1993). Structural and functional diversity in the FGF receptor multigene family. Adv. Cancer Res. 60: 1-41.   Kimura T, Suzuki H, Ohashi T, Asano K, et al. (2001). The incidence of thanatophoric dysplasia mutations in FGFR3 gene is higher in low-grade or superficial bladder carcinomas. Cancer 92: 2555-2561.<2555::AID-CNCR1607>3.0.CO;2-M   Kompier LC, Van Der Aa MN, Lurkin I, Vermeij M, et al. (2009). The development of multiple bladder tumour recurrences in relation to the FGFR3 mutation status of the primary tumour. J. Pathol. 218: 104-112. PMid:19156776   Lopez-Beltran A, Alvarez-Kindelan J, Luque RJ, Blanca A, et al. (2008). Loss of heterozygosity at 9q32-33 (DBC1 locus) in primary non-invasive papillary urothelial neoplasm of low malignant potential and low-grade urothelial carcinoma of the bladder and their associated normal urothelium. J. Pathol. 215: 263-272. PMid:18452128   Miyake M, Sugano K, Kawashima K, Ichikawa H, et al. (2007). Sensitive detection of FGFR3 mutations in bladder cancer and urine sediments by peptide nucleic acid-mediated real-time PCR clamping. Biochem. Biophys. Res. Commun. 362: 865-871. PMid:17803960   Obermann EC, Junker K, Stoehr R, Dietmaier W, et al. (2003). Frequent genetic alterations in flat urothelial hyperplasias and concomitant papillary bladder cancer as detected by CGH, LOH, and FISH analyses. J. Pathol. 199: 50-57. PMid:12474226   Otto W, Denzinger S, Bertz S, Gaumann A, et al. (2009). No mutations of FGFR3 in normal urothelium in the vicinity of urothelial carcinoma of the bladder harbouring activating FGFR3 mutations in patients with bladder cancer. Int. J. Cancer 125: 2205-2208. PMid:19621447   Partanen J, Vainikka S and Alitalo K (1993). Structural and functional specificity of FGF receptors. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 340: 297-303. PMid:8103932   Perez-Castro AV, Wilson J and Altherr MR (1997). Genomic organization of the human fibroblast growth factor receptor 3 (FGFR3) gene and comparative sequence analysis with the mouse Fgfr3 gene. Genomics 41: 10-16. PMid:9126476   Sugano K and Kakizoe T (2006). Genetic alterations in bladder cancer and their clinical applications in molecular tumor staging. Nat. Clin. Pract. Urol. 3: 642-652. PMid:17149381   Tomlinson DC, Baldo O, Harnden P and Knowles MA (2007). FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J. Pathol. 213: 91-98. PMid:17668422 PMCid:2443273   Van Oers JM, Adam C, Denzinger S, Stoehr R, et al. (2006). Chromosome 9 deletions are more frequent than FGFR3 mutations in flat urothelial hyperplasias of the bladder. Int. J. Cancer 119: 1212-1215. PMid:16570285   Van Rhijn BW, Lurkin I, Radvanyi F, Kirkels WJ, et al. (2001). The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res. 61: 1265-1268. PMid:11245416   Van Rhijn BW, Montironi R, Zwarthoff EC, Jobsis AC, et al. (2002). Frequent FGFR3 mutations in urothelial papilloma. J. Pathol. 198: 245-251. PMid:12237885   Van Tilborg AA, de Vries A, de Bont M, Groenfeld LE, et al. (2002). The random development of LOH on chromosome 9q in superficial bladder cancers. J. Pathol. 198: 352-358. PMid:12375268   Wang Y, Spatz MK, Kannan K, Hayk H, et al. (1999). A mouse model for achondroplasia produced by targeting fibroblast growth factor receptor 3. Proc. Natl. Acad. Sci. U. S. A. 96: 4455-4460. PMid:10200283 PMCid:16353
N. L. Satiroglu-Tufan, Dodurga, Y., Gok, D., Cetinkaya, A., and Feitelson, M. A., RNA interference-mediated URG4 gene silencing diminishes cyclin D1 mRNA expression in HepG2 cells, vol. 9, pp. 1557-1567, 2010.
Alao JP (2007). The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol. Cancer 6: 24. PMid:17407548 PMCid:1851974   Arbuthnot P and Kew M (2001). Hepatitis B virus and hepatocellular carcinoma. Int. J. Exp. Pathol. 82: 77-100. PMid:11454100 PMCid:2517704   Feitelson MA and Lee J (2007). Hepatitis B virus integration, fragile sites, and hepatocarcinogenesis. Cancer Lett. 252: 157-170. PMid:17188425   Feitelson MA, Reis HM, Tufan NL, Sun B, et al. (2009). Putative roles of hepatitis B x antigen in the pathogenesis of chronic liver disease. Cancer Lett. 286: 69-79. PMid:19201080 PMCid:2789742   He S, Zhang D, Cheng F, Gong F, et al. (2009). Applications of RNA interference in cancer therapeutics as a powerful tool for suppressing gene expression. Mol. Biol. Rep. 36: 2153-2163. PMid:19117119   Huang J, Zhu B, Lu L, Lian Z, et al. (2009). The expression of novel gene URG4 in osteosarcoma: correlation with patients' prognosis. Pathology 41: 149-154. PMid:18972316   Lahiry P, Torkamani A, Schork NJ and Hegele RA (2010). Kinase mutations in human disease: interpreting genotype-phenotype relationships. Nat. Rev. Genet. 11: 60-74. PMid:20019687   Lian Z, Pan J, Liu J, Zhang S, et al. (1999). The translation initiation factor, hu-Sui1 may be a target of hepatitis B x antigen in hepatocarcinogenesis. Oncogene 18: 1677-1687. PMid:10208429   Lundberg AS and Weinberg RA (1998). Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol. Cell Biol. 18: 753-761. PMid:9447971 PMCid:108786   Park SG, Chung C, Kang H, Kim JY, et al. (2006). Up-regulation of cyclin D1 by HBx is mediated by NF-kappaB2/BCL3 complex through kappaB site of cyclin D1 promoter. J. Biol. Chem. 281: 31770-31777. PMid:16940298   Planchard D, Loriot Y, Goubar A, Commo F, et al. (2009). Differential expression of biomarkers in men and women. Semin. Oncol. 36: 553-565. PMid:19995647   Ruddon RW (2007). Cancer Biology. 4th edn. Oxford University Press, New York.   Satiroglu-Tufan NL, Lian Z, Liu J, Pan J, et al. (2002). Hepatitis B x antigen stimulates expression of a novel cellular gene, URG4, that promotes hepatocellular growth and survival. Neoplasia 4: 355-368. PMid:12082552 PMCid:1531705   Song J, Xie H, Lian Z, Yang G, et al. (2006). Enhanced cell survival of gastric cancer cells by a novel gene URG4. Neoplasia 8: 995-1002. PMid:17217616 PMCid:1783723   Weinberg RA (1995). The retinoblastoma protein and cell cycle control. Cell 81: 323-330.